Whitehead Institute For Biomedical Research

Whitehead Institute For Biomedical Research, a Cambridge, Massachusetts-based nonprofit research organization, is a prime recipient of federal research grants in basic and translational biomedical science, with no federal contracting footprint. The institute operates exclusively as a grant recipient across the National Institutes of Health and other federal research agencies, conducting investigator-led research spanning cell biology, developmental genetics, cancer immunotherapy, and disease mechanisms.

Whitehead Institute's federal portfolio consists primarily of NIH project grants focused on fundamental biological research with applications to human health. Representative recent work includes a $899,850 NIAID award (CFDA 93.855) investigating host cell invasion mechanisms in apicomplexan parasites such as Toxoplasma and Plasmodium, with deliverables including peer-reviewed publications and mechanistic insights into therapeutic targets; a $178,416 NHGRI K99/R00 award (CFDA 93.172) on transcriptional adaptation and trigger RNAs as a novel class of therapeutic molecules for genetic and non-genetic disease; a $173,016 NEI grant (CFDA 93.867) identifying oxidative protective genes to prevent retinal pigment epithelium degeneration in age-related macular degeneration; and a $731,250 Department of the Army Medical Command award under the Military Medical Research and Development program (CFDA 12.420) supporting macrophage immunotherapy research for colorectal cancer. The institute also holds several NIH program project grants on transcriptional regulation, cell-cell communication mechanisms, and stem cell biology, as well as NSF and other agency grants on plant natural products, centromere biology, and epigenetics.

Customer concentration reflects the institute's core position within the NIH ecosystem. The National Institutes of Health accounts for a dominant share of the award count — 92 awards across the main NIH organization and subordinate institutes including the National Institute of General Medical Sciences (21 awards), National Cancer Institute (20 awards), National Institute of Child Health and Human Development, National Institute of Mental Health, National Institute of Allergy and Infectious Diseases, and National Human Genome Research Institute. Department of Defense (14 awards) and other federal research agencies contribute to a portfolio spanning 27 distinct customer agencies, though NIH concentration substantially exceeds all other sources. The institute operates as a prime recipient in 95% of its awards (239 of 251 total); subcontractor work (5%) is routed through major research institutions including The Broad Institute, Dana-Farber Cancer Institute, MIT, Research Triangle Institute, and UC San Francisco on co-funded program projects and collaborative research initiatives.

Activity has moderated in the past five years. The institute recorded 10 awards in 2022, 11 in 2023, 9 in 2024, 6 in 2025, and 3 awards so far in 2026. The combined potential value across all awards in the source stands at $112.5 million, though obligated dollars total $434.8 million, indicating substantial prior-year awards with multi-year terms. Fourteen awards have ultimate completion dates within the next twenty-four months, representing the recompete exposure window for renewal-cycle grant solicitations.

The institute's research capability centers on molecular mechanisms in cell biology, stem cell fate specification and plasticity, developmental biology, transcriptional and epigenetic regulation, cancer immunology, and parasitic disease pathogenesis. Work integrates single-cell and spatial genomics, genome-wide screening platforms, computational modeling, and in vivo disease models to produce mechanistic insights with translational potential in cancer, neurological, metabolic, and infectious disease domains.